ライフサイエンスコーパス: effector cell

1 n the HA and its sialic acid receptor on the effector cell.

2 ession of CCR4 in circulating Treg but not T effector cells.

3 exposed, tolerance-prone RTEs into competent effector cells.

4 d by their different roles as T memory and T effector cells.

5 ed in therapeutic effects mediated by murine effector cells.

6 tiated into tissue-invasive, proinflammatory effector cells.

7 a heterogeneous population of primary immune effector cells.

8 erential apoptosis of Treg compared with CD8 effector cells.

9 sis from bona fide Tregs, rather than from T-effector cells.

10 maR interaction unable to optimally activate effector cells.

11 imulate Th1-type cytotoxic T cells and other effector cells.

12 ll proliferation and polarization toward TH1 effector cells.

13 xhibited gene expression of memory precursor effector cells.

14 nd function for these tissue-resident innate effector cells.

15 onse toward long-lived memory or short-lived effector cells.

16 al pathogens that have suitable receptors on effector cells.

17 n membrane-anchored form on activated immune effector cells.

18 response modifiers and recruitment of immune effector cells.

19 marily by modulating immune and inflammatory effector cells.

20 8(+) T cells expressing B7-H1 are functional effector cells.

21 mune responses of these central inflammatory effector cells.

22 tracellular matrix and eliminate the primary effector cells.

23 responses or blocks the functions of immune effector cells.

24 ells into inflammatory IFN-gamma-coproducing effector cells.

25 ed CD4(+) T cells by CD8(+) T cells or other effector cells.

26 tokine-induced signal transduction in immune effector cells.

27 but also in the nature of pathogenic immune effector cells.

28 ed by autologous serum antibodies and innate effector cells.

29 er (NK) cells via binding to CD16A as immune effector cells.

30 te the kinetics of cytolytic activity by the effector cells.

31 to cognate death ligands expressed on immune-effector cells.

32 and cytokine production of FVIII-specific T-effector cells.

33 tributed to neuronal control of target organ effector cells.

34 ADCC killing mediated by autologous sera and effector cells.

35 ors on subsets of innate and adaptive immune effector cells.

36 on on Th2 cells, and marked highly activated effector cells.

37 lating SIRT1 cleavage in draining lymph node effector cells.

38 th the emergence of hybrid Th1-Th17 and Th17 effector cells.

39 cacy against cancer by recruiting key immune effector cells.

40 body-coated virus-infected cell by cytotoxic effector cells.

41 gesting an important role for macrophages as effector cells.

42 rare, antigen-specific T lymphocytes to form effector cells.

43 rise to IL-7-responsive polyfunctional CD4+ effector cells.

44 silonRI-bound IgE on the surface of allergic effector cells.

45 thin the phagolysosome and in the cytosol of effector cells.

46 oxp3 expression to become IL-4-producing TH2 effector cells.

47 cells isolated from normal donors served as effector cells.

48 ulting immune complexes and the magnitude of effector cell activation and in vivo inflammation.

49 FNAR KO bone marrow were unable to control T effector cell activation and tissue inflammation.

50 port that FcgammaRIIB-mediated inhibition of effector cell activation requires direct ligation to an

51 l and direct cofactor to drive antiviral Th1 effector cell activation, with implications for vaccinat

52 requirement of immune complex formation for effector cell activations.

53 Here we show that Th1 effector cells also express ST2 upon differentiation in

54 sing high (regulatory T cells, Treg) or low (effector cells) amounts of IL-2Ralpha (CD25).

55 f a mAb bound to HA with the FcgammaR of the effector cell and (ii) the interaction between the HA an

56 called by restimulation, analogous to T-cell effector cell and memory cell generation.

57 contained an increase in CD4(+) Th1 and Th17 effector cells and a reduced ratio of regulatory T cells

58 rized by a CD4 T cell differentiation toward effector cells and by a lower frequency of IFN-gamma pro

59 eadily activated, long-lasting population of effector cells and contribute to the early phases of imm

60 Suppressive capacity of Tregs on effector cells and cytokines was assessed.

61 llografts have suppression of alloreactive T effector cells and delayed acute rejection.

62 ptor FcgammaRIIB is co-expressed on allergic effector cells and has been implicated in negative regul

63 longed intratumor persistence of the OT1 CTL-effector cells and improved function with focused and co

64 however, identified macrophages as prominent effector cells and induction of antibody-dependent cell

65 f intratumoral but not systemic Tregs into T effector cells and leads to enhanced antitumor immunity.

66 Antibody secreting cells (ASCs) are critical effector cells and long-lived sentinels for immune memor

67 L-17, and thus share features of TH1 or TH17 effector cells and lose suppressive function.

68 Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antige

69 n and recruitment of disease-fighting immune effector cells and pathways.

70 ad less severe dysfunctions in innate immune effector cells and preserved functional T-cell responses

71 oglia, which function as both primary immune effector cells and professional phagocytes in the centra

72 ent increased leukocytes and CD4+ and CD8+ T-effector cells and reduced myeloid-derived suppressor ce

73 +) T cell produces terminally differentiated effector cells and renews itself for continued defense.

74 aRIIB with FcepsilonRI-bound IgE on allergic effector cells and represents an efficient dual-modality

75 ponses, including the induction of cytotoxic effector cells and the secretion of noncytolytic soluble

76 by inducing proinflammatory responses in CD4 effector cells and Treg pathways.

77 especially, the interactions between immune effector cells and tumor cells in adoptive immunotherapy

78 phages were not cleared by pulmonary immune effector cells and were immunologically well tolerated b

79 ll by using perforin and gzmB (gzmB(+)Tc) as effector cells and wild type as well as Bim- or Bak/Bax-

80 cessive mechanisms leading to elimination of effector cells and, simultaneously, a dominant mechanism

81 cing vascular inflammation in vivo, identify effector cells, and ascertain specific receptors and pat

82 tion via IL-2RbetagammaC displayed on immune effector cells, and binding to Fcgamma receptors on natu

83 olate keratinocytes, dendritic cells, CD4+ T effector cells, and CD8+ T effector cells from healthy s

84 the roles of IgE and IgG antibodies, immune effector cells, and mediators thought to contribute to e

85 ve CD8(+) T cells expand, differentiate into effector cells, and then contract to a long-lived pool o

86 cells differentiate into different types of effector cells: antibody-producing plasma cells, germina

87 ystander protection of nontransfected immune effector cells as measured by CD3zeta chain expression i

88 nsically limited in comparison with other Th effector cells, as the biological role of a GC Tfh cell

89 in DNA methylation programming at naive and effector cell-associated genes in virus-specific CD8 T c

90 o both human CD3 and CD123 to mediate target-effector cell association, T-cell activation, proliferat

91 duces targeted cell lysis in the presence of effector cells at as low as sub-picomolar concentrations

92 ution to immunity of major subsets of immune effector cells (B cells, CD4(+) and CD8(+) T cells) in a

93 d role for macrophages as anti-mycobacterial effector cells, badger macrophage (bdMphi) responses rem

94 in brain (RHEB) failed to differentiate into effector cells but retained memory characteristics, such

95 production, promoting phagocytosis of immune effector cells, but not inducing peripheral lymphocyte a

96 ce regulatory T-cell conversion from naive T effector cells, but, importantly, the regulatory T cells

97 d activation of dendritic cells and allergic effector cells by adaptive immune mechanisms that involv

98 gest that recruitment of FcgammaR-expressing effector cells by antibodies is a major in vivo mechanis

99 and adaptive immunity through activation of effector cells by antigen-antibody complexes.

100 lymphocytes indicated that differentiated T effector cells can elicit durable antitumor responses in

101 ntiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of pr

102 in the CXCR3 axis drives both the anti-tumor effector cell chemoattraction and pro-tumor infiltration

103 Proliferating casein/T-effector cell counts were measured in children with CM-F

104 B and T cells are important effector cells delaying the spread of pneumococci from t

105 required destination, and differentiate into effector cells, depending on the local tissue environmen

106 When MLC effector cells derived from a G14D-CCV-immunized fish we

107 ty to provide long-term immunity while other effector cells develop into terminally differentiated ef

108 nhibition of Foxp3 expression in response to effector cell-differentiating cytokines.

109 CD5 modified effector cell-differentiating signals that inhibit Treg

110 WASP that is required for prevention of Th2 effector cell differentiation and allergic sensitization

111 NMT3a as a crucial regulator of CD8(+) early effector cell differentiation and effector versus memory

112 al role in T regulatory cells to contain Th2 effector cell differentiation and prevent allergic sensi

113 everal junctures of B lineage maturation and effector cell differentiation by controlling B cell acti

114 parts that require peripheral activation for effector cell differentiation, gammadelta T cells instea

115 ates LFA-1 affinity, dictated Tfh versus Th2 effector cell differentiation.

116 Antigen receptor affinity also influenced effector cell differentiation.

117 elements in signature genes associated with effector cell differentiation.

118 targeting CD8(+) T cells and led to impaired effector cell differentiation.

119 innate lymphoid cells (ILC2s) are important effector cells driving the initiation of type 2 immune r

120 T cells and neutrophils represent the major effector cells driving this inflammatory reaction wherea

121 have been suggested as the anti-inflammatory effector cells during helminth infections.

122 f the Nfia gene normally differentiated into effector cells during sepsis, cleared infecting bacteria

123 differentiation after priming, termed "early effector cells" (EEC), which also exhibited an activated

124 th broad utility in terms of both target and effector cell engagement.

125 lineating the effect of complement-dependent effector-cell engagement in various therapeutic settings

126 onverted from suppressor cells to pathogenic effector cells, enhancing lung allergic responses, but t

127 type 3 innate lymphoid cells (ILC3), innate effector cells essential for barrier immunity.

128 These results suggest that delayed effector cell expansion and stochastic variability in ef

129 nity than do splenic memory T cells, whereas effector cells express TCRs of similar high affinity in

130 tiation, regulated the formation of terminal-effector cell fates and memory-precursor cell fates, res

131 Macrophages are also the key effector cell for mAb therapies.

132 ceptor modulation, and engagement of myeloid effector cells for antibody-dependent cell-mediated cyto

133 es of IgA isotype effectively engage myeloid effector cells for cancer immunotherapy.

134 ralize the pathogen or recruit innate immune effector cells for help.

135 tic cells, CD4+ T effector cells, and CD8+ T effector cells from healthy skin samples, followed by RN

136 mory cells embody features of both naive and effector cells, fuelling a long-standing debate centred

137 expansion has been linked to loss of immune effector cell function and reduced efficacy of immune-ba

138 cules with the NKG2D receptor and influences effector cell function.

139 study, we defined the bioenergetics of Th17 effector cells generated in vivo.

140 cell expansion and stochastic variability in effector cell generation due to an initially small naive

141 reas fully activated (CD62L(lo)CD27(-)) late effector cells have a terminal Teff phenotype (PD-1(+),

142 lls and produce IgE immunoglobulins that arm effector cells; however, mouse models are inconclusive o

143 chlamydia and establish neutrophils as a key effector cell in this response.

144 lop more memory precursor and fewer terminal effector cells in a T-cell intrinsic manner compared wit

145 te of allergic inflammation and are critical effector cells in allergic diseases.

146 Mast cells are key effector cells in allergic reactions.

147 Mast cells are important effector cells in allergy, with sentinel cell roles in h

148 e functions of IgE antibodies and associated effector cells in both antitumour immune surveillance an

149 is study highlights the importance of innate effector cells in establishing a broad-spectrum antivira

150 Platelets are the chief effector cells in hemostasis.

151 Neutrophils are key effector cells in inflammation and play an important rol

152 of hapten-specific IFN-gamma-producing CD8 T effector cells in LNs.

153 scuss the evolving insight of macrophages as effector cells in mAb therapy and address novel (co)ther

154 ) T cell activation and development into Th1 effector cells in neonates is essential to the successfu

155 D8(+) T cells to differentiate into terminal effector cells in response to microbial infection.

156 Activated fibroblasts are the key effector cells in SSc responsible for the excessive prod

157 nt is accompanied by decreases in numbers of effector cells in target organs, including mast cells, b

158 Monocytes are phagocytic effector cells in the blood and precursors of resident a

159 control point in the accumulation of innate effector cells in the intestine and in the spatio-tempor

160 B cells contributed also to expansion of TH2 effector cells in the lungs and central memory T cells i

161 thogenic site, the gut, and retained these T effector cells in the systemic sites, leading to augment

162 However, we observed Th1/Th17 effector cells in the tumor draining lymph node and tumo

163 fected target cells by HIV-1-specific CD8(+) effector cells in vitro Among persons expressing protect

164 esidence time enables durable attenuation of effector cells in vitro and in vivo.

165 spontaneous diminution of graft infiltrating effector cells, including CD11b(-)Gr-1(+) cells and acti

166 the activation and antifungal activities of effector cells, including NK cells and macrophages.

167 In humans GPR15 is expressed by effector cells, including pathogenic TH2 cells in ulcera

168 to allergens, for example, by desensitizing effector cells, inducing regulatory T and B lymphocytes

169 Macrophages were the predominant effector cells infiltrating WT and SHP-1(-/-) muscle, an

170 pten-specific CD8 T cells, and a decrease in effector cell influx in inflamed tissue.

171 a model for the differentiation of terminal effector cells initiated by an early burst of transcript

172 Rather than acting as isolated effector cells, innate cells are in constant communicati

173 phils and show the importance of an antibody/effector cell interaction in mediating humoral immunity.

174 sion of short-lived tumor antigen-specific T effector cells into long-lived T memory cells.

175 ss of DNMT3a biases differentiation of early effector cells into memory precursor cells.

176 Recruitment of innate immune effector cells into sites of infection is a critical com

177 by T helper 17 (TH17) cells (CD4(+) T helper effector cells involved in multiple inflammatory conditi

178 Basophils are important effector cells involved in the pathogenesis of inflammat

179 mma receptors (FcgammaRs) on numerous immune effector cells is almost universal, and here we review t

180 -binding region of the HA and sialic acid on effector cells is required for optimal activation.

181 CD27(+)/CD45RA(-) Th1-like effector cells killed K562 target cells through a mechan

182 ts, and natural killer (NK) cells are immune effector cells known to eliminate both virus-infected an

183 We examined the time course of effector cell markers (for basophils, dendritic cells an

184 driver of Th1 differentiation and cytotoxic effector cell maturation.

185 induce direct apoptosis and activate immune effector cells may provide benefit over existing treatme

186 mizing cell surface accessibility and immune effector cell mediated antitumor activity.

187 We demonstrate that effector-cell-mediated killing is essential for the obse

188 In contrast, early IL-2 signals induce effector cell metabolic profiles that are more conducive

189 Propionate suppressed T effector cell migration between the intestine and the sp

190 These cells may derive from memory precursor effector cells (MPECs), which are distinct from short-li

191 and forms antigen-specific memory precursor effector cells (MPECs), which ultimately develop into me

192 effector cells (SLECs) and memory precursor effector cells (MPECs).

193 failed to constrain autoimmune colitis and T effector cells neither provided a protective response to

194 These data suggest that tissue resident effector cell numbers and low FcgammaR expression may li

195 anti-PD-1 Ab treatment did not alter immune effector cell numbers or myeloid cell activation.

196 Mast cells (MCs), the primary effector cell of the atopic response, participate in imm

197 allergens and IgE cross-linking capacity in effector cells of allergy.

198 ic mesenchymal cells are known to be the key effector cells of fibroproliferative disease, but the sp

199 The effector cells of fibrosis are activated fibroblasts cal

200 EMT-driven generation of myofibroblasts, the effector cells of fibrosis that produce excessive extrac

201 ays that are required for the recruitment of effector cells of the immune response.

202 irect the clearance of HIV-infected cells by effector cells of the immune system.

203 les with the ability to recruit and activate effector cells of the immune system.

204 Neutrophils are key effector cells of the innate immune response to pathogen

205 ng natural antibodies and are considered key effector cells of the innate immune response.

206 Neutrophils are key effector cells of the innate immune system.

207 Blood monocytes are heterogeneous effector cells of the innate immune system.

208 ntred on whether memory T cells develop from effector cells or directly from naive cells.

209 cient in the antibodies, antibody receptors, effector cells, or mediators implicated in anaphylaxis a

210 Similarly, elevated T effector cell polarization within blood and brain tissue

211 support the view that an IFN-gamma-activated effector cell population cooperates with antibody to pro

212 T lymphocytes constitute a major effector cell population in autoimmune type 1 diabetes.

213 tection is dependent on the activation of an effector cell population in genital tract tissues by CD4

214 od myeloid mononuclear cells represent a key effector cell population in this model of virus-induced

215 ppears to be necessary for activation of the effector cell population that functions in antibody-medi

216 1-d-old mice generated a 2W:I-A(b)-specific effector cell population that peaked later than in adult

217 ic antibody response or to recruitment of an effector cell population to genital tract tissue.

218 reviously unappreciated IL-10 producing ILC2 effector cell population.

219 macrophage helper compositions that matched effector cell populations generated much earlier in the

220 Aberrant immune activation mediated by T effector cell populations is pivotal in the onset of aut

221 necessitates interactions with FcgammaRs on effector cell populations to mediate in vivo protection.

222 onses were favored by high concentrations of effector cells postinjection, such as induced by higher

223 er enhanced immune surveillance and superior effector cell potency against cancer cells.

224 cells into CD127(low)KLRG1(high) short-lived effector cells, preferentially expanding the CD127(high)

225 Regulatory T cells (Treg ) suppress T effector cell proliferation and maintain immune homeosta

226 e responses by directing activity of various effector cells rather than serving as effectors themselv

227 antibodies, which have higher affinities for effector cell receptors and perform potent immune functi

228 rrying the S239D/I332E mutation for improved effector cell recruitment (CD19-DE).

229 Such mast cell responses might enhance effector cell recruitment during RSV-induced disease.

230 ducted, we considered and calibrated a tumor-effector cell recruitment model under the influence of f

231 is study were protective through Fc-mediated effector cell recruitment.

232 ing that changes in integrin ligation on the effector cells regulate the kinetics of cytolytic activi

233 Due to their ability to suppress effector cells, regulatory T cells (Tregs) have been pro

234 to characterize the breadth of the antiviral effector cell response and to determine the contribution

235 ing Ca(2+) entry regulates a wide variety of effector cell responses including transcription, motilit

236 utralizing role of antibodies in stimulating effector cell responses may have been a key mechanism of

237 y exert their effect by activating antiviral effector cell responses rather than virus neutralization

238 ynamic models with cytolytic or noncytolytic effector cell responses.

239 ontrol both T follicular helper cell and Th1 effector cell responses.

240 for optimal protection; however, the innate effector cells responsible for mediating this protection

241 amplified and sustained polyfunctional CD4+ effector cells, resulting in improved therapeutic outcom

242 tifibrotic efficacy or the identity of their effector cell(s).

243 of cultured cells, as well as recruit immune effector cells, selected an antibody that later emerged

244 Th1 effector cells selectively drive CF both in vitro and in

245 o main populations of effectors: short-lived effector cells (SLECs) and memory precursor effector cel

246 In vitro generated CD4+ T effector cells stimulated in the presence of a PI3Kdelta

247 specification and differentiation of CD4+ T effector cell subsets.

248 of complement activation on the capacity of effector cells such as mononuclear cells (MNC) and polym

249 nfected CD4+ T cells by recruiting cytotoxic effector cells, such as natural killer cells, monocytes,

250 cells typically results in the formation of effector cells (TE) as well as phenotypically distinct m

251 lymphocytes, enhanced the polarization of T effector cells (TH1/TH17), and decreased the production

252 suppression was more pronounced in terminal effector cells than in memory precursor cells and was re

253 (CTLs) provide a readily available source of effector cells that can be administered with minimal tox

254 y against infections by differentiating into effector cells that contribute to rapid pathogen control

255 dered neutrophils to function as nonspecific effector cells that die quickly after performing antimic

256 ate into fibrocytes, which serve as emerging effector cells that enhance cell proliferation in wound

257 lymphoid cells (ILCs) are a family of immune effector cells that have important roles in host defense

258 (MPECs), which are distinct from short-lived effector cells that provide acute protection but are oft

259 s favored differentiation into memory versus effector cells, the former of which are superior in medi

260 e of an extremely high number of circulating effector cells, thought to be necessary to scan, locate,

261 They can activate effector cells, thus amplifying liver damage, and by mod

262 strategies to recruit and redirect cytotoxic effector cells to eliminate the HIV-1 latently infected

263 its differentiation intermediates and mature effector cells to expand upon demand, thereby providing

264 regulation plays a permissive role enabling effector cells to initiate and perpetuate tissue damage,

265 also have the potential to guide host immune effector cells to kill HIV-1-infected cells.

266 and paracrine signaling loops that can alert effector cells to sites of infection but also provides a

267 t lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (alphaCD20-IL-

268 to infection and cancer by promoting immune effector-cell trafficking into inflamed tissue.

269 ral killer cells constitute a critical human effector cell type.

270 -mediated Ab functions mediated by different effector cell types and against different viral targets.

271 These findings suggest that diverse effector cell types arise in the primary immune response

272 D4(+) T cell produces a distinctive ratio of effector cell types early in the immune response that is

273 We also discuss various inflammatory effector cell types involved in cytokine production, rem

274 win pairs discordant for T1D in three immune effector cell types.

275 ) T cells can be reprogrammed into cytotoxic effector cells upon therapeutic costimulatory signaling

276 geting the surface-bound IgE of the allergic effector cells via low-affinity anti-human IgE Abs with

277 T suppressor cells that ex vivo reverted to effector cells were described in the 1980s.

278 Effector cells were evaluated using in vitro human cell

279 Effector cells were evaluated with in vitro human cell c

280 nd that both Ezh2-deficient Treg cells and T effector cells were functionally impaired in vivo: Tregs

281 IL-25 receptor (IL-17RB)-expressing TH2 effector cells were identified in nasal polyp tissue but

282 lts were seen when chronic infection-induced effector cells were transferred into mice infected with

283 f naive T cells into T-helper type 17 (Th17) effector cells, which are essential in vaccine immunity

284 and reversion of their phenotype to non-TFH effector cells, which ultimately resulted in breakdown o

285 le platform for promoting differentiation of effector cells while at the same time enabling self-rene

286 immune-shaping by affecting mainly CD4(+) T effector cells while sparing CD4(+)Foxp3(+) Treg cells h

287 atural killer (NK) cells are critical innate effector cells whose development is dependent on the Jan

288 Stimulation of effector cells with IL-2 downregulated mRNA expression o

289 ss T cell oxidative metabolism, resulting in effector cells with metabolic needs that cannot be met.

290 h led to E-protein-dependent accumulation of effector cells with mixed characteristics during viral i

291 erentiate under inflammatory conditions into effector cells with non-redundant functions, such as den

292 ymorphonuclear neutrophils (PMNs) are innate effector cells with pivotal roles in pathogen recognitio

293 ppress the proliferation of FVIII-specific T-effector cells with specificity for a different FVIII do

294 ferentiation is set to produce myriad immune effector cells with the ability to respond to multitudin

295 mAbs can bridge immune effector cells with tumor cells, which can result in ant

296 lation of TH1-type CD4(+) T cells and immune effector cells within affected organs, most frequently t

297 une system, facilitating the distribution of effector cells within nearly all compartments of the bod

298 that IFNgamma promotes AML blasts to act as effector cells within the context of antibody therapy.

299 Group 2 innate lymphoid cells (ILC2s) are effector cells within the mucosa and key participants in

300 and conversion of intratumoral Tregs into T effector cells within the tumor microenvironment.